The invention discloses a
gemcitabine drug sensitive marker, a detection kit and application of the
gemcitabine drug sensitive marker, the
gemcitabine drug sensitive marker is a gemcitabine drug-resistant marker or / and a gemcitabine sensitive marker, and the gemcitabine drug-resistant marker is one or more of ATOH8, DAPK2, BCL2L2, PNPLA2, SHROOM1, FGGY, CPQ, CPO, SLC10A5,
ADAMTS15, COL25A1, ASMTL and ENSG00000286264; the sensitive marker is one or more of FAM163A, KREMEN2, VPS37D, GGCT (Growth Growth
Computed Tomography), ADSL (Asymmetrical Digital Subscriber Loop), FOXL2 (Focal OXL2), MAST1 (MAST1), DNAAF3 (
Deoxyribose Nucleic Acid Amplified The gemcitabine drug sensitive marker is used for predicting the
drug effect of gemcitabine. According to the present invention, the expression of the related molecules is detected through the sequencing of the tissue
transcriptome of the
urothelial carcinoma patient, or through the PCR, the
gene chip, the
tissue chip, the NanoString technology, the
immunohistochemistry and the
ELISA method, and the guidance is provided for the drug use of gemcitabine and the precise treatment of
bladder cancer.